The Hematology Research Unit

Annual report 2022

OUH
Odense
University Hospital
Svendborg Hospital

Hæmatologisk
afdeling

SDU

Region of
Southern Denmark

Introduction

This is the second annual report from our Research Unit.

The Hematology Department was established in 2003, and the Research Unit was established in 2004.

Since 2017, Head of Research has been professor Niels Abildgaard, e-mail: niels.abildgaard@rsyd.dk

Daily manager in the unit is Pia Kirsten Pedersen, e-mail: pia.k.pedersen@rsyd.dk

Research secretary is Vickie Svane Kristensen, e-mail: vickie.svane.kristensen@rsyd.dk

Our first annual report provided a thorough description of the historical development of our unit. It can be found on our website, https://www.sdu.dk/en/forskning/haematologi

The report for 2022 focuses on our achievements in 2022.

Major achievements in 2022

Tarec El-Galaly, professor at Aalborg University Hospital, appointed as adjunct professor at SDU, the Hematology Research Unit. In total, we now have 3 adjunct professors and 3 professors in the Research Unit.

We consolidated our function and activities in early phase clinical trials, including activation of new “first-in-human” (FIH) studies. Consultant Jacob Haaber Christensen has the delegated responsibility for the FIH study activities and is principal investigator in all initiated FIH studies.

We initiated our first clinical CAR-T-cell study, which is a study using cellular therapy with *in vitro* manipulated T-cells.

There are six ongoing PhD-studies. Find a short description of the projects later in the report. Find completed theses at

https://www.sdu.dk/en/forskning/haematologi/phd-projekter

About this report

We have reached our major goals for research activity and production in 2022. The following pages summarize our

- Organization
- Research Teams
- Research Centers
- User Council for Research
- Clinical trial activity
- Research production
- Research grants
- PhD projects
- List of peer-reviewed publications in 2022

Our organization

Our human resources in 2022 counted a total of 40 employees, including TAPs and named VIPs

- 3 professors, Niels Abildgaard (Head of Research), Henrik Frederiksen (Clinical Professor), Charlotte Guldborg Nyvold (Professor in Molecular Hematology)
- Daily manager Pia K. Pedersen
- 5 associate clinical professors, Thomas Stauffer Larsen, Thomas Lund, Claus Marcher, Duruta Weber, Lene Granfeldt Østgaard
- Associate professor in Nursing Research Nana Hyldig
- 3 adjunct professors, Madeleine King, Ole Weiss Bjerrum and Tarec El-Galaly
- 5 Post docs – Jakub Krejcik, Lene Kongsgaard Nielsen, Rikke Faebo Larsen, Marcus Høy Hansen, Simone Valentin Hansen
- 6 PhD students
- Research coordinator/fundraiser Tine Rosenberg
- Specialist senior consultant Sally Grant
- 3 clinical project nurses and 12 study coordinators
- 2 secretaries, including research secretary Vickie Svane Kristensen

Plasma cell neoplasms

The research team is headed by Professor Niels Abildgaard.

Primary research areas of the team are multiple myeloma, AL amyloidosis, and Waldenstrom macroglobulinemia. The research includes clinical research, basic laboratory research, and research within the fields of health-related quality of life, patient-reported outcome (PRO), and health economics.

Diagnostics and treatment of multiple myeloma bone disease and AL amyloidosis are areas of particular interest. Several clinical trials within these areas are conducted.

Niels Abildgaard heads Odense Amyloidosis Centre, AmyC OUH, appointed as center of clinical excellence in 2017.

Senior researchers in the team are associate professor, consultant, PhD Thomas Lund, consultant, PhD Charlotte Toftmann Hansen, staff specialist, PhD Ida Bruun Kristensen and staff specialist, PhD Jakub Krejcik. Three PhD-studies are ongoing, and three part-time post docs are active within the team.

The team is represented in several academic study groups, including the Danish Myeloma Study Group (DMSG), the Nordic Myeloma Study Group (NMSG), the European Myeloma Network (EMN), the International Society of Amyloidosis (ISA), and the International Myeloma Working Group (IMWG). Through these collaborations, the department participates in several research protocols.

Benign hematology and epidemiology

The team is headed by Professor Henrik Frederiksen.

Primary research areas of the team are frequency and complications of a variety of benign hematological diseases, including hemolytic anemias, congenital red blood cell diseases, immune thrombocytopenia, and TTP. Moreover, age, comorbidity and complications of hematological cancer as well as risk of new cancer are studied.

Randomized, controlled studies are conducted together with studies on Quality of Life. Other methods include mathematical modeling and artificial intelligence/machine learning.

Senior researchers in the team are MD, PhD Dennis Lund Hansen. One PhD-study, two research assistant studies and one pre-graduate projects are ongoing.

The team collaborates with national researchers and groups across Denmark within epidemiology, biostatistics, and hematology. International collaborations extend to France, Italy, Norway, Holland, UK, and USA. Through these collaborations, the department also participates in several clinical research protocols.

Malignant lymphomas

MD, PhD, Associate Professor, Thomas Stauffer Larsen heads the research team.

Other senior researchers are professor, Henrik Frederiksen; staff specialist, PhD, Karen Juul-Jensen, staff specialist, PhD, Peter Brændstrup, and consultant, PhD, Jacob Haaber Christensen.

The primary research area of the team is B-cell lymphomas, which are explored through both clinical and basic laboratory research. In addition, register-based research is conducted to uncover the prevalence and prognosis of different lymphoma subtypes. One PhD study is currently ongoing. Moreover, the team runs a large number of clinical trials, covering early phase 1 to post-registration, phase 4 trials.

The team is represented in the Danish Lymphoma Group (DLG) and the Nordic Lymphoma Group (NLG) and is engaged in international collaborative groups conducting clinical trials, such as European Mantle Cell Network and International Extranodal Lymphoma Study Group (IELSG).

The team actively participates in collaborations with the Centre for Cellular Immunotherapy of Hematological Cancer Odense (CITCO) and the Academy of Geriatric Cancer Research (AgeCare) at OUH.

Adjunct professor Tarec El-Galaly is particularly involved in the research of this team.

Myeloid disorders

The research team is headed by MD, PhD, Associate Professor Claus W. Marcher.

Primary research areas of the team are myelodysplastic syndrome, acute leukemia, mastocytosis, and hypereosinophilic syndrome. The research includes clinical research, stem cell research, register-based research, and basic laboratory research.

Other senior researchers include associate professor, consultant, PhD, Duruta Weber; associate professor, consultant, DMSc, PhD, Lene Østgaard Granfeldt; consultant Klas Raaschou-Jensen, consultant Andreja Dimitrijevic, consultant Mette Brabrand, staff specialist, PhD Lene Østergaard Jepsen, staff specialist Gunhild Thomsen and Head of department, PhD Hanne Vestergaard.

Further, Adjunct Professor, DMSc Ole Weiss-Bjerrum is associated with the research of the team.

The team actively participates in the Mastocytosis Center OUH (MastOUH) and the Center for Eosinophilia Odense (CEOS). Moreover, the team is represented in several academic study groups including the Acute Leukemia Group (ALG), the Danish Society for Chronic Myeloproliferative Diseases (DSKMS), the Nordic CML Study Group, the Nordic MDS Group (NMDS), and the Nordic AML Group (NAMLG).

Cancer biology and molecular hematology

Professor Charlotte Guldborg Nyvold heads the Hematology-Pathology Research Laboratory, (HPF).

At HPF, the research team conducts laboratory research within the field of hematology in close collaboration with hematologists at the Department of Hematology and hematopathologists and laboratory technicians at the Department of Pathology. The molecular heterogeneity of malignant B-cell diseases, specifically, malignant B cell lymphomas and multiple myeloma is of particular interest. The research team possess expertise in a wide range of molecular techniques, such as biobanking, flow cytometry, cell sorting, functional cell culture studies, and next generation sequencing, including exome and whole genome sequencing, transcriptome sequencing, long-read sequencing, and single cell sequencing.

Senior researchers in the team are molecular biologist and bioinformatician, PhD Marcus Høy Hansen, molecular biologist, PhD Oriane Cédile, and molecular biologist, PhD Simone Valentin Hansen. Three PhD-studies and two pre-graduate projects are ongoing, as well as the daily management of our biobank.

The team is represented in several academic study groups including the Nordic Myeloma Study Group (NMSG) and is involved in both national and international collaborations.

Research Group for Supportive Care

The research team is headed by associate professor, nurse, MSc, PhD Nana Hyldig.

This is a new research team established in 2022. The primary research areas are supportive care, covering the whole spectrum from diagnosis to terminally ill patients.

The team is cross-disciplinary, and both quantitative and qualitative research methods are applied. Patient and relatives perspectives are in focus, and use of patient reported outcome measurements (PROM) is integrated in collaboration with our Quality of Life Research Center (QoL Research OUH).

Other senior researchers in the team are professor Niels Abildgaard, professor Henrik Frederiksen, staff specialist, PhD Lene Østergaard Jepsen, and other leading researchers in the team are MD Louise Redder, nurse, MSc Anne Møller Clausen, developmental nurse Birgit Jakobsen, and User Council representatives.

The team is closely integrated with QoL Research OUH where our adjunct professor Madeleine King is associated.

Two PhD studies are upcoming, and two pre-graduate projects are ongoing.

Research Centers

The Hematology Research Unit host:

The **Quality of Life Research Center**, QoL Research OUH, center coordinator is MSc, Tine Rosenberg, e-mail: tine.rosenberg@rsyd.dk

The center of clinical excellence, **Odense Amyloidosis Center**, AmyC OUH, www.amyloidosis.dk , center director is professor Niels Abildgaard, e-mail: niels.abildgaard@rsyd.dk

The Hematology Research Unit are partners in the following OUH based Research Centers:

CITCO – Center for Cellular Immunotherapy in Hematological Cancer

MastOUH – Center for Mastocytosis

AgeCare – Academy of Geriatric Cancer Research

CEOS – Center for Eosinophilia Odense

PREmedico – Multidisciplinary OUH Center for precision medicine

User Council for Research

To strengthen the dialogue and collaboration with patients and relatives, we established a User Council for Research at the Department of Hematology in 2017. Currently, six patients and one relative comprise the Council.

Three times a year, the Council is invited to dialogue meetings at the department, where upcoming and ongoing projects are discussed, and achieved research results are presented and discussed.

Between meetings, the user councilors are involved in writing layman paragraphs for e.g. grant applications, patient information material, among other things.

In 2022, we have expanded the collaboration and involved user representatives as project partners in some projects, and the council was also represented in employment committees.

The User Council is invited to participate in our research events and seminars at the Department of Hematology.

2017-2022, Clinical Trials



We have continued high activity in initiating and running clinical trials. In 2022, 16 new clinical trials were initiated.

2018-2022
Initiated trials by study phase category



In recent years, it has been our strategy to increase the number of early phase 1-2 clinical trials, which typically involve treatment with new therapeutics.

We plan to establish a “Phase 1 Unit”, which will allow us to formalize the running of early phase studies.

2018-2022
Initiated studies by sponsor category



It is our goal to balance initiation of investigator-initiated clinical trials (IICT) and trials that are initiated and sponsored by pharmaceutical companies. As expected, there is some year-to-year variation in this.

2017-2022 Publications



Overall, since 2017, we have been successful in increasing the number of peer-reviewed publications as well as the number of first and/or last authorships. In 2022, we see a minor decrease in the number of publications.

Journal ranking

Publications in Top Journal Percentiles by SJR

Entity: Haematology May 2023 · Year range: 2017 to 2023 · Data source: Scopus, up to 03 May 2023 · Filters: Only Scholarly Output published at University of Southern Denmark included

Share of publications in Haematology May 2023 that are in the top journals by SJR



126 (34.2%)

number of publications in the top 10% journals by SJR

According to OUH/SDU goals, 40% of publications should be in Scimago Journal Rank top 10%.
This has nearly been achieved (34.2%).

Journal ranking

Publications by Journal quartile

Entity: Haematology May 2023 · Year range: 2017 to 2023 · Data source: Scopus, up to 03 May 2023 · Filters: Only Scholarly Output published at University of Southern Denmark included

Share of publications per Journal quartile by SJR



Quartiles	Publications	Publication share (%)
Q1 (top 25%)	266	72.3
Q2 (26% - 50%)	75	20.4
Q3 (51% - 75%)	15	4.1
Q4 (76% - 100%	12	3.3

Cumulative shares	Publications	Publication share (%)
Q1 to Q2 (top 50%)	341	92.7
Q1 to Q3 (top 75%)	356	96.7

According to OUH/SDU goals, 80% of publications should be in Scimago Journal Rank top 25%.
This has nearly been reached (72.3%).

Citation Impact

Field-Weighted Citation Impact

Entity: Haematology May 2023 · Year range: 2017 to 2023 · Data source: Scopus, up to 03 May 2023 · Filters: Only Scholarly Output published at University of Southern Denmark included



1.30

Field-Weighted Citation Impact of Haematology May 2023

According to OUH/SDU goals, the field-weighted citation impact should be above 1.0.
This has persistently been achieved.

Citations

Citations per Publication

Entity: Haematology May 2023 · Year range: 2017 to 2023 · Data source: Scopus, up to 03 May 2023 · Filters: Only Scholarly Output published at University of Southern Denmark included



14.6

average number of citations per publication in Haematology May 2023

Journal ranking

Field-Weighted Citation Impact

Entity: OUH Haematology March 2022 · Year range: 2016 to 2022 · Data source: Scopus, up to 30 Mar 2022 · Filters: Only Scholarly Output published at University of Southern Denmark included ·



1.60

Field-Weighted Citation Impact of OUH Haematology March 2022

According to OUH/SDU goals, the field-weighted citation impact should be above 1.0.
This has persistently been achieved.

Funding





In 2022, we submitted applications for a total of DKK 71.2 mio, hereof 67.2 to external funds. This is so far the largest sum ever that we have applied for. However, disappointingly, we were only granted DKK 2.4 mio from external funds (granted/applied = 3.6%). External funding constituted 56%.

Ongoing PhD study

Monitoring circulating tumor DNA in aggressive large B-cell lymphoma – a tool for personalized medicine

PhD student: MD Gayaththri Vimalathas

Aggressive large B-cell lymphoma is the most frequent type of lymphoma with an annual incidence of approximately 450 cases in Denmark. The disease is deadly, but with immuno-chemotherapy, 60-65% can be cured. Unfortunately, 30-40% of the patients will relapse or are primary refractory. When treatment is completed, the patients undergo an end-of-treatment imaging scan and enroll in a monitoring program consisting of regular clinical examinations and imaging scans. It can be difficult to determine, if activity seen on imaging scans is caused by lymphoma activity or benign conditions. Further, it is not always possible to obtain tissue biopsies for diagnostic clarification. Clinicians therefore need a more sensitive and easily accessible method that allows for longitudinal monitoring to detect residual disease and thus identify patients at risk of relapse earlier. The aim of this PhD project is to evaluate the potential utility of circulating tumor DNA in aggressive large B-cell lymphoma as a novel molecular biomarker of minimal residual disease using Next Generation Sequencing in a real-life, clinically feasible set-up. The perspectives of our project are to obtain greater diagnostic accuracy, more timely therapeutic intervention in case of residual disease or relapse, and ultimately improved patient survival.

Supervisors: MD, PhD, Associate Professor Thomas Stauffer Larsen, Department of Hematology, OUH; Professor, PhD, Msc. Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; MD, Associate Professor Michael Boe Møller, Department of Pathology, OUH; Bioinformatician, PhD Marcus Høy Hansen, Hematology-Pathology Research Laboratory, Department of Hematology, OUH.

Ongoing PhD study

Prognostication in multiple myeloma

PhD student: MD Louise Redder

It can be difficult to predict how things will develop, when a patient is diagnosed with multiple myeloma. Many prognostic models have tried, but the models are not tested in the general myeloma population and are therefore not used in clinical work. The purpose of this PhD project is to verify which model can provide the most accurate prognosis for patients with multiple myeloma.

Using data from the Danish Myeloma Registry and the National Patient Registry, we will validate proposed prognostic models in the Danish myeloma population. Towards the end of the project, we will examine whether quality of life can be used to determine the prognosis. Identifying the most precise prognostic model will provide the best basis for selecting patients' treatment.

Supervisors: Professor Niels Abildgaard, Department of Hematology, OUH; Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD, Associate Professor Lene Kongsgaard Nielsen, Department of Hematology, OUH; Biostatistician, Associate Professor Sören Möller, OPEN, OUH.

Ongoing PhD study

The role of mesenchymal stromal cell and bone marrow stromal dysfunction in multiple myeloma

PhD student: MD Mette Bøegh Levring

Many patients with multiple myeloma (MM) suffer from the debilitating complication of lytic bone disease, causing fractures, pain, and immobilization; all affecting patients' quality of life. Research shows that the cause of lytic bone disease is interaction between the malignant plasma cells and the stromal cells in the bone marrow. In this 3-year PhD-project, we investigate the bone marrow stroma of patients with multiple myeloma. We will focus on the bone forming osteoblasts and their precursor cells, mesenchymal stromal cells. We will examine the cells with both functional cell cultures and genetic transcription to characterize the cells in great detail. We will compare the characteristics of stromal cells from different stages of multiple myeloma and from healthy donors. Our mission is to understand how stromal cells are involved in the development of lytic bone disease. A better understanding of this will facilitate development of new treatment for bone disease, improving quality of life for many patients with MM.

Supervisors: Professor Niels Abildgaard, Department of Hematology, OUH; Professor Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; Professor Moustapha Kassem, Laboratory of Molecular Endocrinology, Department of Endocrinology, OUH; MD, PhD Ida Bruun Kristensen, Department of Hematology, OUH.

Ongoing PhD study

Treatment and Monitoring of the Bone Disease in Multiple Myeloma Patients

PhD student: MD Michael Tveden Gundesen

Bone disease in multiple myeloma (MM) leads to severe pain and suffering. Though great improvements have been obtained in the treatment of MM, healing the bone disease remains a clinical challenge. This project aims to evaluate the bone-healing potential of ixazomib and to determine the best method for monitoring the bone disease by evaluating the effect of different imaging modalities.

The bone-healing potential of ixazomib is tested in an explorative study of 30 patients with MM associated bone disease receiving ixazomib. Patients are followed for 2 years of treatment and evaluated by NaF-CT scans.

In another study, we follow 267 patients receiving treatment with zometa for two to four years. Zometa is a well-proven protective agent for bone disease in MM, but the treatment is not without side effects, and the optimal treatment period is unknown. The hope is that we will be able to determine the optimal treatment period to secure an optimal treatment effect with fewest possible side effects. This study is conducted in collaboration with centers of the Nordic Myeloma Study Group.

Supervisors: MD, PhD Thomas Lund, Department of Hematology, OUH; Professor Niels Abildgaard, Department of Hemaology, OUH; Clinical director of Oncoradiology Jon Thor Asmussen, Department of Radiology, OUH; MD Anne Lerberg Nielsen, Department of Nuclear Medicine, OUH.

Ongoing PhD study

On adverse outcomes in immune thrombocytopenia – a population-based cohort study

PhD student: MD Nikolaj Mannering

Immune thrombocytopenia (ITP) is an acquired autoimmune disease characterized by a low number of circulating platelets in the bloodstream. Patients suffer from bleedings, treatment toxicity, reduced quality of life and shortened life expectancy. It is believed that disease complications and side effects from treatment contribute equally to complications and excess mortality. However, these observations are based on a very small number of patients and frequencies. Impact of complications from disease and treatment are not well understood.

Using data from Danish health registries, our study therefore aims at providing up-to-date knowledge on possible and yet unexplored complications and late effects to ITP. We have constructed a large population-based cohort comprising >5,000 patients with ITP and >200,000 age-sex matched comparisons from the Danish population. The patients were diagnosed during the period 1980-2016 and have complete follow-up.

During this period, the treatment options for ITP have changed radically. We will use our data to provide updated mortality and adverse health outcome effects, focusing particularly on temporal variation. Our dataset is unprecedented in this field of research.

We aim at conveying results to clinicians in order to optimize treatment, follow-up and to improve outlook for patients with ITP.

Supervisors: Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD Dennis Lund Hansen, Department of Hematology, OUH; Professor Anton Pottegård, Department of Public Health, University of Southern Denmark.

Ongoing PhD study

Drug resistance in patients with chronic lymphocytic leukemia

PhD student: MSc Sólja Remisdóttir Veyhe

Chronic lymphocytic leukemia is the most common type of leukemia in adults with about 450 new cases in Denmark annually. Although promising results have been obtained with the targeted treatments, ibrutinib and venetoclax, some patients still experience poor treatment response. The aim of the project is to provide novel and valuable information on the molecular pathways and kinetics involved in resistance to these drugs. The hope is that this will enable us to predict who will benefit from the treatment, before treatment start. Further, it might enable early detection of the development of resistance during treatment.

Thus, the project has the potential to influence the clinical course of each individual patient, both before and during treatment.

Supervisors: Professor Charlotte Guldborg Nyvold, Hematology-Pathology Research Laboratory, Department of Hematology, OUH; Professor Henrik Frederiksen, Department of Hematology, OUH; MD, PhD Karen Juul-Jensen, Department of Hematology, OUH; Professor Karen Dybkær, Department of Clinical Medicine, Aalborg University Hospital.

Peer-reviewed publications in 2022

STAT3 is over-activated within CD163^{pos} bone marrow macrophages in both Multiple Myeloma and the benign pre-condition MGUS

Andersen, M. N., Andersen, N. F., Lauridsen, K. L., Etzerodt, A., Sorensen, B. S., **Abildgaard, N.,** Plesner, T., Hokland, M. & Møller, H. J., jan. 2022, I: Cancer Immunology, Immunotherapy. 71, 1, s. 177–187

Late recurrence of lymphoid malignancies after initial treatment for Hodgkin lymphoma – A study from the Danish Lymphoma Registry

Andersen, M. D., Hamilton-Dutoit, S., Modvig, L., Vase, M., Christiansen, I., **Christensen, J. H**., Dahl-Sørensen, R. B., Stoltenberg, D., Kamper, P. & d'Amore, F., jul. 2022, I: British Journal of Haematology. 198, 1, s. 50-61

What are patients first-time experiences with video consulting? A qualitative interview study in Danish general practice in times of COVID-19

Assing Hvidt, E., **Christensen, N. P**., Grønning, A., Sutherland Jepsen, C. & Lüchau, E. C., 15. apr. 2022, I: BMJ Open. 12, 4, e054415

Cancer risk in persons with new-onset anaemia: a population-based cohort study in Denmark

Boennelykke, A., Jensen, H., **Østgård, L. S. G.,** Falborg, A. Z., Hansen, A. T., Christensen, K. S. & Vedsted, P., 21. jul. 2022, I: BMC Cancer. 22, 13 s., 805.

Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59

Brennan, K., Iversen, K. F., Blanco-Fernández, A**., Lund, T**., Plesner, T. & Gee, M. M. M., 25. okt. 2022, I: Cells. 11, 21, 19 s., 3365.

HPV Test as Test of Cure After Conization for CIN2+: A Nationwide Register-Based Cohort Study

Bruhn, L. V., **Hyldig, N**. & Schledermann, D., 1. okt. 2022, I: Journal of Lower Genital Tract Disease. 26, 4, s. 287-292

A polygenic risk score for multiple myeloma risk prediction

Canzian, F., Piredda, C., Macauda, A., Zawirska, D., Andersen, N. F., Nagler, A., Zaucha, J. M., Mazur, G., Dumontet, C., Wątek, M., Jamroziak, K., Sainz, J., Várkonyi, J., Butrym, A., Beider, K., **Abildgaard, N**., Lesueur, F., Dudziński, M., Vangsted, A. J., Pelosini, M., Subocz, E., Petrini, M., Buda, G., Raźny, M., Gemignani, F., Marques, H., Orciuolo, E., Kadar, K., Jurczyszyn, A., Druzd-Sitek, A., Vogel, U., Andersen, V., Reis, R. M., Suska, A., Avet-Loiseau, H., Kruszewski, M., Tomczak, W., Rymko, M., Minvielle, S. & Campa, D., apr. 2022, I: European Journal of Human Genetics. 30, 4, s. 474-479

Healthcare resource utilization in patients with myeloproliferative neoplasms: A Danish nationwide matched cohort study

Christensen, S. F., Svingel, L. S., Kjærsgaard, A., Stenling, A., Darvalics, B., Paulsson, B., Andersen, C. L., Christiansen, C. F., Stentoft, J., Starklint, J., Severinsen, M. T., Clausen, M. B., Hilsøe, M. H., Hasselbalch, H. C., **Frederiksen, H**., Mikkelsen, E. M. & Bak, M., nov. 2022, I: European journal of haematology. 109, 5, s. 526-541

Monocytosis in primary care and risk of haematological malignancies

Christensen, M. E., Siersma, V., Kriegbaum, M., Lind, B. S., Samuelsson, J., **Ostgard, L. S. G**., Gronbaek, K. & Andersen, C. L., 7. dec. 2022, (E-pub ahead of print) I: European journal of haematology.

Extramedullary Hematopoiesis Visualized on FDG-PET/CT in a Patient with Beta-Thalassemia

Dahlsgaard-Wallenius, S. E., **Juul-Jensen, K**., Nielsen, A. L. & Hildebrandt, M. G., dec. 2022, I: Nuclear Medicine and Molecular Imaging. 56, 6, s. 328-330

Assessing how routes to diagnosis vary by the age of patients with cancer: a nationwide register-based cohort study in Denmark

Danckert, B., Christensen, N. L., Falborg, A. Z., **Frederiksen, H**., Lyratzopoulos, G., McPhail, S., Pedersen, A. F., Ryg, J., Thomsen, L. A., Vedsted, P. & Jensen, H., 19. aug. 2022, I: BMC Cancer. 22, 13 s., 906.

Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer

Ehmsen, S., Asmussen, A., Jeppesen, S. S., Nilsson, A. C., Kragh, A., **Frederiksen, H.** & Ditzel, H. J., 8. aug. 2022, I: Cancer Cell. 40, 8, s. 800-801

Exploration of residual disease in stem cell products from mantle cell lymphoma using next-generation sequencing

Elkjær, L. A. L., **Cédile, O., Hansen, M. H**., Nielsen, C., Møller, M. B., **Abildgaard, N., Haaber, J. & Nyvold, C. G.,** jan. 2022, I: Leukemia Research Reports. 18, 5 s., 100341.

Sinonasal B-cell lymphomas: A nationwide cohort study, with an emphasis on the prognosis and the recurrence pattern of primary diffuse large B-cell lymphoma

Eriksen, P. R. G., Clasen-Linde, E., Nully Brown, P. D., Haunstrup, L., **Christoffersen, M**., Asdahl, P., Thomsen, T. M., Harwood, C. D., Heegaard, S. & Buchwald, C. V., apr. 2022, I: Hematological Oncology. 40, 2, s. 160-171

NK- and T-cell lymphoma of the nasal cavity and paranasal sinuses in Denmark 1980–2017: a nationwide cohort study

Eriksen, P. R. G., Clasen-Linde, E., Brown, P. D. N., Haunstrup, L., **Christoffersen, M**., Asdahl, P., Thomsen, T. M., von Buchwald, C. & Heegaard, S., nov. 2022, I: Leukemia and Lymphoma. 63, 11, s. 2579-2588

Clinical Presentation and Outcome of Sinonasal Extraosseous Plasmacytoma in Denmark: A Nationwide Cohort From 1980 to 2017

Eriksen, P. R. G, Khkbaz, E., Clasen-Linde, E., Brown, P. D. N, Haunstrup, L., **Christoffersen, M.**, Asdahl P., Thomsen T. M., Gerner-Rasmussen J., Heegaard ,S., von Buchwald, C.

Udfordringer ved kræftbehandling til ældre

Ewertz, M., Ehmsen, S., Jørgensen, T. L., Dieperink, K. B., Pfeiffer, P., Hansen, O., Brink, C., Hjelmborg, J. V. B., Hvidt, N. C., **Abildgaard, N**., Lund, L., **Frederiksen, H**., Ryg, J. & Ditzel, H., 21. mar. 2022, I: Ugeskrift for læger. 184, 6, 9 s., V04210325.

CNS prophylaxis for diffuse large B-cell lymphoma

Eyre, T. A., Savage, K. J., Cheah, C. Y., **El-Galaly, T. C**, Lewis, K. L., McKay, P., Wilson, M. R., Evens, A. M., Bobillo, S., Villa, D., Maurer, M. J., Cwynarski, K. & Ferreri, A. J. M., sep. 2022, I: The Lancet Oncology. 23, 9, s. e416-e426

Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience

Fattizzo, B., Cecchi, N., Bortolotti, M., Giordano, G., Patriarca, A., Glenthøj, A., Cantoni, S., Capecchi, M., Chen, F., Mingot-Castellano, M. E., Napolitano, M., **Frederiksen, H**., Gonzaléz-Lopez, T. J. & Barcellini, W., 18. aug. 2022, I: Blood. 140, 7, s. 789-792

Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine

Gigoux, M., Holmström, M. O., Zappasodi, R., Park, J. J., Pourpe, S., Bozkus, C. C., Mangarin, L. M. B., Redmond, D., Verma, S., Schad, S., George, M. M., Venkatesh, D., Ghosh, A., Hoyos, D., Molvi, Z., Kamaz, B., Marneth, A. E., Duke, W., Leventhal, M. J., Jan, M., Ho, V. T., Hobbs, G. S., Knudsen, T. A., Skov, V., Kjær, L., **Larsen, T. S**., **Hansen, D. L**., Lindsley, R. C., Hasselbalch, H., Grauslund, J. H., Lisle, T. L., Met, Ö., Wilkinson, P., Greenbaum, B., Sepulveda, M. A., Chan, T., Rampal, R., Andersen, M. H., Abdel-Wahab, O., Bhardwaj, N., Wolchok, J. D., Mullally, A. & Merghoub, T., 15. jun. 2022, I: Science Translational Medicine. 14, 649, eaba4380.

Impact of C-reactive protein and albumin levels on short, medium, and long term mortality in patients with diffuse large B-cell lymphoma

Gradel, K. O., Larsen, T. S., **Frederiksen, H**., Vinholt, P. J., Iachina, M., Póvoa, P., Zampieri, F. G., Nielsen, S. L., Dessau, R. B., Møller, J. K., Jensen, T. G., Chen, M., Coia, J. E. & Jelicic, J., 2022, I: Annals of Medicine. 54, 1, s. 713-722

Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group

Gregersen, H., Peceliunas, V., Remes, K., Schjesvold, F., **Abildgaard, N.,** Nahi, H., Andersen, N. F., Vangsted, A. J., Klausen, T. W., Helleberg, C., Carlson, K., Frølund, U. C., Axelsson, P., Stromberg, O., Blimark, C. H., Crafoord, J., Tsykunova, G., **Eshoj, H. R**., Waage, A., Hansson, M. & Gulbrandsen, N., jan. 2022, I: European journal of haematology. 108, 1, s. 34-44

A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma

Gundesen, M. T., Asmussen, J. T., Haukås, E., Schubert, M., **Abildgaard, N**., Schjesvold, F. & **Lund, T**., maj 2022, I: European journal of haematology. 108, 5, s. 423-429

Mantle cell lymphoma and the evidence of an immature lymphoid component

Hansen, S. V., **Nyvold, C. G. & Hansen, M. H**., apr. 2022, I: Leukemia Research. 115, 106824.

Survival in autoimmune hemolytic anemia remains poor, results from a nationwide cohort with 37 years of follow-up

Hansen, D. L., Möller, S. & **Frederiksen, H**., jul. 2022, I: European journal of haematology. 109, 1, s. 10-20

Germline GATA1s generating mutations predispose to leukemia with acquired trisomy 21 and Down syndrome-like phenotype

Hasle, H., Kline, R. M., Kjeldsen, E., Nik-Abdul-Rashid, N. F., Bhojwani, D., Verboon, J. M., DiTroia, S. P., Chao**, K. R., Raaschou-Jensen**, K., Palle, J., Zwaan, C. M., **Nyvold, C. G**., Sankaran, V. G. & Cantor, A. B., 26. maj 2022, I: Blood. 139, 21, s. 3159-3165

Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., **Vilmar, A.,** Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J-M., Jiménez-Ubieto, A., Fischer, L., Eyre, T. A., Keeping, S., Park, J. E., Wu, J. J., Siddiqi, R., Reitan, J., Wade, S. & Salles, G., 18. okt. 2022, (E-pub ahead of print) I: British Journal of Haematology.

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

Horwitz, S., O'Connor, O. A., Pro, B., Trümper, L., Iyer, S., Advani, R., Bartlett, N. L., **Christensen, J. H**., Morschhauser, F., Domingo-Domenech, E., Rossi, G., Kim, W. S., Feldman, T., Menne, T., Belada, D., Illés, Á., Tobinai, K., Tsukasaki, K., Yeh, S-P., Shustov, A., Hüttmann, A., Savage, K. J., Yuen, S., Zinzani, P. L., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M. & Illidge, T., mar. 2022, I: Annals of Oncology. 33, 3, s. 288-298

A retrospective cohort study of patients with eosinophilia referred to a tertiary centre

Hougaard, M., Thomsen, G. N., Kristensen, T. K., Lindegaard, H. M., Davidsen, J. R., Hartmeyer, G. N., Kjeldsen, A. D., Martin-Iguacel, R., Maiborg, M., Assing, K., Andersen, C. L., Broesby-Olsen, S., Møller, M. B**., Vestergaard, H. & Bjerrum, O. W**., apr. 2022, I: Danish Medical Journal. 69, 4, A07210558.

Comparative evaluation of the heterozygous variant standard deviation as a quality measure for next-generation sequencing

Høy Hansen, M., Steensboe Lang, C., **Abildgaard, N. & Nyvold, C. G**., nov. 2022, I: Journal of Biomedical Informatics. 135, 104234.

Clonal hematopoiesis is associated with hematological toxicity during lenalidomide-based therapy for MCL

Husby, S., Bæch-Laursen, C., Eskelund, C. W., Favero, F., Jespersen, J. S., Hutchings, M., Pedersen, L. B., Niemann, C. U., Weischenfeldt, J., Räty, R., **Larsen, T. S.,** Kolstad, A., Jerkeman, M. & Grønbæk, K., dec. 2022, I: Leukemia. 36, 12, s. 2912-2916

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load

Hussmann, D., Starnawska, A., Kristensen, L., Daugaard, I., Thomsen, A., Kjeldsen, T. E., Hansen, C. S., Bybjerg-Grauholm, J., Johansen, K. D., Ludvigsen, M., Kristensen, T., **Larsen, T. S**., Møller, M. B., **Nyvold, C. G.**, Hansen, L. L. & Wojdacz, T. K., apr. 2022, I: Haematologica. 107, 4, s. 877-886

Methylation microarray-based detection of clinical copy-number aberrations in CLL benchmarked to standard FISH analysis

Hussmann, D., Starnawska, A., Kristensen, L., Daugaard, I., **Cédile, O.**, Nguyen, V. Q., Kjeldsen, T. E., Hansen, C. S., Bybjerg-Grauholm, J., Kristensen, T., **Larsen, T. S.,** Møller, M. B., **Nyvold, C. G**., Hansen, L. L. & Wojdacz, T. K., nov. 2022, I: Genomics. 114, 6, 10 s., 110510.

IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia

Huuhtanen, J., Ilander, M., Yadav, B., Dufva, O. M., Lähteenmäki, H., Kasanen, T., Klievink, J., Olsson-Strömberg, U., Stentoft, J., Richter, J., Koskenvesa, P., Höglund, M., Söderlund, S., Dreimane, A., Porkka, K., Gedde-Dahl, T., Gjertsen, B. T., Stenke, L., Myhr-Eriksson, K., Markevärn, B., Lübking, A., **Dimitrijevic, A.,** Udby, L., **Bjerrum, O. W**., Hjorth-Hansen, H. & Mustjoki, S., 1. sep. 2022, I: The Journal of clinical investigation. 132, 17, 17 s., e152585.

High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells from Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens

Iversen, K. F., Nederby, L., **Lund, T**. & Plesner, T., sep. 2022, I: Clinical Hematology International. 4, s. 107-116

Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark

Jakobsen, L. H., Øvlisen, A. K., Severinsen, M. T., Bæch, J., Kragholm, K. H., Glimelius, I., Gang, A. O., Jørgensen, J. M., **Frederiksen, H.,** Poulsen, C. B., Clausen, M. R., Pedersen, P. T., Pedersen, R. S., Torp-Pedersen, C., Eloranta, S. **& El-Galaly, T. C**., 27. jan. 2022, I: Blood Cancer Journal. 12, 7 s., 16.

Clinical Characteristics and Management of Patients With Concomitant Liver Cirrhosis and Lymphoma: A Systematic Review

Jelicic, J., **Larsen, T. S**., Fialla, A. D., Bukumiric, Z. & Andjelic, B., nov. 2022, I: Clinical Lymphoma, Myeloma and Leukemia. 22, 11, s. e981-e991

Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study

Juul, M. B., Jelicic, J., Anru, P. L., Engberg, H., Hammershøj Jensen, P., Kristensen, H. B., Baech, J., Clausen, M. R., Gang, A. O., Munksgaard, L., **El-Galaly, T. C., Frederiksen, H. & Stauffer Larsen, T**., sep. 2022, I: Leukemia and Lymphoma. 63, 9, s. 2074-2083

Fusion transcript analysis reveals slower response kinetics than multiparameter flow cytometry in childhood acute myeloid leukaemia

Karlsson, L., **Nyvold, C. G.,** Soboli, A., Johansson, P., Palmqvist, L., Tierens, A., Hasle, H., Lausen, B., Jónsson, Ó. G., Jürgensen, G. W., Ebbesen, L. H., Abrahamsson, J. & Fogelstrand, L., dec. 2022, I: International Journal of Laboratory Hematology. 44, 6, s. 1094-1101

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Kater, A. P., Levin, M. D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., van der Kevie-Kersemaekers, A. M. F., Dobber, J. A., Poulsen, C. B., **Frederiksen, H**., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Brieghel, C., Mattsson, M., Bellido, M., Tran, H. T. T., Nasserinejad, K. & Niemann, C. U., jun. 2022, I: The Lancet Oncology. 23, 6, s. 818-828

Kognitive senfølger efter trombotisk trombocytopenisk purpura

Kiib Kristensen, C., Rosenstrøm, B., **Lund Hansen, D.,** Nilsson, A. C. & **Frederiksen, H.,** 22. aug. 2022, I: Ugeskrift for Laeger. 184, 16, V03220180.

Home is best. Self-administration of subcutaneous Bortezomib at home in patients with multiple myeloma - A mixed method study

Kirkegaard, J., Lundholm, B. W., Rosenberg, T., Lund, T., Gundesen, M. T. & Dieperink, K. B., 1. okt. 2022, I: European journal of oncology nursing : the official journal of European Oncology Nursing Society. 60, 7 s., 102199.

Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses

Knudsen, T. A., Skov, V., Stevenson, K. E., Werner, L., Duke, W., Laurore, C., Gibson, C. J., Nag, A., Thorner, A. R., Wollison, B., **Hansen, D. L.,** Ellervik, C., El Fassi, D., de Stricker, K., Ocias, L. F., **Brabrand, M**., **Bjerrum, O. W.,** Overgaard, U., **Frederiksen, M**., Kristensen, T., Kruse, T., Thomassen, M., Mourits-Andersen, T., Severinsen, M. T., Stentoft, J., Starklint, J., Neuberg, D., Kjaer, L., **Larsen, T. S.,** Hasselbalch, H. C., Lindsley, R. C. & Mullally, A., 12. apr. 2022, I: Blood Advances. 6, 7, s. 2107-2119

Surgical resection of glioblastomas induces pleiotrophin-mediated self-renewal of glioblastoma stem cells in recurrent tumors

Knudsen, A. M., Halle, B., **Cédile, O.,** Burton, M., Baun, C., Thisgaard, H., Anand, A., Hubert, C., Thomassen, M., Michaelsen, S. R., Olsen, B. B., Dahlrot, R. H., Bjerkvig, R., Lathia, J. D. & Kristensen, B. W., 1. jul. 2022, I: Neuro-Oncology. 24, 7, s. 1074-1087

Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions

Kristensen, K. B., Lund, L. C., Jensen, P. B., Broe, A., **Rotbain, E.,** Damkier, P., Pottegård, A., Andersen, J. H., Højlund, M., Olesen, M., Rasmussen, L., Hansen, M. R., Ernst, M. T., Wesselhoeft, R., Henriksen, D. P., Reilev, M., Bliddal, M. & Hallas, J., 2022, I: Clinical Epidemiology. 14, s. 567-579

Effects of chemotherapy dose reductions in overweight patients with acute myeloid leukaemia: A Danish nationwide cohort study

Kristensen, D. T., Nielsen, L. B., Jakobsen, L. H. K., Kristensen, T. C. C., **Jepsen, L. Ø.,** Schöllkopf, C., Theilgaard-Mönch, K., **El-Galaly, T. C**., Roug, A. S. & Severinsen, M. T., nov. 2022, I: British Journal of Haematology. 199, 4, s. 539-548

Positive predictive values of hematological procedure codes in the Danish National Patient Registry—A population-based validation study

Lauritsen, T. B., Nørgaard, J. M., Christensen, M. E., Dalton, S. O. & **Østgård, L. S. G**., sep. 2022, I: Pharmacoepidemiology and Drug Safety. 31, 9, s. 963-971

Socioeconomic position and clinical outcomes in patients with myelodysplastic syndromes: A population-based cohort study

Lauritsen, T. B., **Østgård, L. S. G**., Grønbæk, K., Dalton, S. O. & Nørgaard, J. M., dec. 2022, I: Hematological Oncology. 40, 5, s. 1056-1066

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients with Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease on Presentation to Hospital

Lee, R. J., Wysocki, O., Zhou, C., Shotton, R., Tivey, A., Lever, L., Woodcock, J., Albiges, L., Angelakas, A., Arnold, D., Aung, T., Banfill, K., Baxter, M., Barlesi, F., Bayle, A., Besse, B., Bhogal, T., Boyce, H., Britton, F., Calles, A., Castelo-Branco, L., Copson, E., Croitoru, A. E., Dani, S. S., Dickens, E., Eastlake, L., Fitzpatrick, P., Foulon, S., **Frederiksen, H**., Frost, H., Ganatra, S., Gennatas, S., Glenthøj, A., Gomes, F., Graham, D. M., Hague, C., Harrington, K., Harrison, M., Horsley, L., Hoskins, R., Huddar, P., Hudson, Z., Jakobsen, L. H., Joharatnam-Hogan, N., Khan, S., Khan, U. T., Khan, K., Massard, C., Maynard, A., McKenzie, H., Michielin, O., Mosenthal, A. C., Obispo, B., Patel, R., Pentheroudakis, G., Peters, S., Rieger-Christ, K., Robinson, T., Rogado, J., Romano, E., Rowe, M., Sekacheva, M., Sheehan, R., Stevenson, J., Stockdale, A., Thomas, A., Turtle, L., Viñal, D., Weaver, J., Williams, S., Wilson, C., Palmieri, C., Landers, D., Cooksley, T., Dive, C., Freitas, A. & Armstrong, A. C., 2022, I: JCO clinical cancer informatics. 6, 18 s., e2100177.

Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network

Ludwig, H., Boccadoro, M., Moreau, P., San-Miguel, J., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T., Driessen, C., Hajek, R., Dimopoulos, M. A., Gay, F., Avet-Loiseau, H., Terpos, E., Zojer, N., Mohty, M., Mateos, M-V., Einsele, H., Delforge, M., Caers, J., Weisel, K. C., Jackson, G., Garderet, L., Engelhardt, M., van de Donk, N., Leleu, X., Goldschmidt, H., Beksac, M., Nijhof, I., **Abildgaard, N**., Bringhen, S. & Sonneveld, P., 2022, I: Kompass Onkologie. 9, 1, s. 3-12

Factors associated with risk and prognosis of intensive care unit admission in patients with acute leukemia: a Danish nationwide cohort study

Maeng, C. V., Christiansen, C. F., Liu, K. D., Kamper, P., Christensen, S., Medeiros, B. C. & **Østgård, L. S. G**., okt. 2022, I: Leukemia and Lymphoma. 63, 10, s. 2290-2300

The changing landscape of treatment options in childhood acute lymphoblastic leukaemia

Micallef, B., Nisticò, R., Sarac, S. B., **Bjerrum, O. W.,** Butler, D., Sammut Bartolo, N., Serracino-Inglott, A. & Borg, J. J., maj 2022, I: Drug Discovery Today. 27, 5, s. 1483-1494

Outcomes and endpoints in clinical trials supporting the marketing authorisation of treatments in paediatric acute lymphoblastic leukaemia

Micallef, B., Nistico, R., **Bjerrum, O. W.,** Sarac, S. B., Butler, D., Serracino-Inglott, A. & Borg, J. J., sep. 2022, I: Drug Discovery Today. 27, 9, s. 2440-2466

Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (ERCI) network

Moulis, G., Cooper, N., Ghanima, W., González-López, T., Kühne, T., Lozano, M. L., Michel, M., Provan, D., Zaja, F., Aladjidi, N., Christiansen, C. F., **Frederiksen, H**., Grainger, J., McDonald, V., Robinson, S., Schifferli, A. & Rodeghiero, F., jun. 2022, I: British Journal of Haematology. 197, 5, s. 633-638

A national Danish proof of concept on feasibility and safety of home -based intensive chemotherapy in patients with acute myeloid leukemia

Nørskov, K. H., Fridthjof, K., Kampmann, P., Dünweber, A., Andersen, C. L., Renaberg, T., Schöllkopf, C., Ahmad, S. A., Schou, K., Jensen, C. F., Møller, P., **Lundholm, B. W**., **Marcher, C**., **Østergaard Jepsen, L**., Ørntoft, A. K., Ommen, H. B., Andersen, L., Behrentzs, A., Hasselgren, C. F., Severinsen, M., Grand, M. K., Jarden, M., Møller, T. & Kjeldsen, L., jan. 2022, I: Leukemia Research. 112, 106756.

Safety and efficacy of durvalumab with R-CHOP or R^2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Nowakowski, G. S., Willenbacher, W., Greil, R., **Larsen, T. S.,** Patel, K., Jäger, U., Manges, R. F., Trümper, L., Everaus, H., Kalakonda, N., Brown, P., Jørgensen, J. M., Cunningham, D., Dell'Aringa, J., Fox, B., Rubio, N. D., Kilavuz, N., Casadebaig, M. L., Manzke, O. & Munoz, J., feb. 2022, I: International Journal of Hematology. 115, 2, s. 222-232

Mental health among patients with non-Hodgkin lymphoma: A Danish nationwide study of psychotropic drug use in 8750 patients and 43 750 matched comparators

Øvlisen, A. K., Jakobsen, L. H., Kragholm, K. H., Nielsen, R. E., de Nully Brown, P., Dahl-Sørensen, R. B., **Frederiksen, H**., **Mannering, N.,** Josefsson, P. L., Ludvigsen Al-Mashhadi, A., Jørgensen, J. M., Dessau-Arp, A., Clausen, M. R., Pedersen, R. S., Torp-Pedersen, C., Severinsen, M. T. & **El-Galaly, T**. C., 1. jun. 2022, I: American Journal of Hematology. 97, 6, s. 749-761

Classification of amyloidosis by model-assisted mass spectrometry-based proteomics

Palstrøm, N. B., Rojek, A. M., Møller, H. E. H., **Hansen, C. T**., Matthiesen, R., Rasmussen, L. M., **Abildgaard, N**. & Beck, H. C., 1. jan. 2022, I: International Journal of Molecular Sciences . 23, 1, 11 s., 319.

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”

Rasmussen, B., Göhring, G., Bernard, E., Nilsson, L., Tobiasson, M., Jädersten, M., Garelius, H., Dybedal, I., Grønbaek, K., Ejerblad, E., Lorenz, F., Flogegård, M., **Marcher, C. W.,** Öster Fernström, A., Cavelier, L., Papaemmanuil, E., Ebeling, F., Kittang, A. O., Nørgaard, J. M., Saft, L., Möllgård, L. & Hellström-Lindberg, E., maj 2022, I: Leukemia. 36, 5, s. 1436-1439

The role of E3 ubiquitin ligase in multiple myeloma: potential for cereblon E3 ligase modulators in the treatment of relapsed/refractory disease

Richardson, P. G., Mateos, M-V., Vangsted, A. J., Ramasamy, K., **Abildgaard, N**., Ho, P. J., Quach, H. & Bahlis, N. J., 2022, I: Expert Review of Proteomics. 19, 4-6, s. 235-246

The CLL comorbidity index in a population-based cohort: a tool for clinical care and research

Rotbain, E. C., Gordon, M. J., Vainer, N., **Frederiksen, H**., Hjalgrim, H., Danilov, A. V. & Niemann, C. U., 26. apr. 2022, I: Blood Advances. 6, 8, s. 2701-2706

The use of proxies and proxy-reported measures: a report of the international society for quality of life research (ISOQOL) proxy task force

Roydhouse, J. K., Cohen, M. L., **Eshoj, H. R**., Corsini, N., Yucel, E., Rutherford, C., Wac, K., Berrocal, A., Lanzi, A., Nowinski, C., Roberts, N., Kassianos, A. P., Sebille, V., **King, M. T.,** Mercieca-Bebber, R. & on behalf of the ISOQOL Proxy Task Force and the ISOQOL Board of Directors, feb. 2022, I: Quality of Life Research. 31, 2, s. 317-327

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Savage, K. J., Horwitz, S. M., Advani, R., **Christensen, J. H**., Domingo-Domenech, E., Rossi, G., Morschhauser, F., Alpdogan, O., Suh, C., Tobinai, K., Shustov, A., Trneny, M., Yuen, S. L. S., Zinzani, P. L., Truemper, L. H., Illidge, T. M., O'Connor, O. A., Pro, B., Miao, H., Bunn, V., Fenton, K., Fanale, M., Puhlmann, M. & Iyer, S. P., 11. okt. 2022, I: Blood Advances. 6, 19, s. 5550-5555

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

Schmitz, A., Brøndum, R. F., Johnsen, H. E., Mellqvist, U. H., Waage, A., Gimsing, P., Op Bruinink, D. H., van der Velden, V., van der Holt, B., Hansson, M., Andersen, N. F., Frølund, U. C., Helleberg, C., Schjesvold, F. H., Ahlberg, L., Gulbrandsen, N., Andreasson, B., Lauri, B., Haukas, E., Bødker, J. S., Roug, A. S., Bøgsted, M., Severinsen, M. T., Gregersen, H., **Abildgaard, N.,** Sonneveld, P. & Dybkær, K., 5. feb. 2022, I: BMC Cancer. 22, 11 s., 147.

Acute myeloid leukemia exhibiting clonal instability during treatment: Implications for measurable residual disease assessments

Simonsen, A. T., Meggendorfer, M., Hansen, M. H., Nederby, L., Koch, S., Hansen, M., Rosenberg, C. A., Kern, W., **Nyvold, C. G.,** Aggerholm, A., Haferlach, T. & Ommen, H. B., mar. 2022, I: Experimental Hematology. 107, s. 51-59

The impact of an education intervention on the approach of hospital staff to patients with dementia in a Danish general hospital setting: An explanatory sequential mixed-methods study

Toubøl, A., Moestrup, L., Thomsen, K., Ryg, J., **Lund Hansen, D.,** Foldager, M., Jakobsen, S. & Nielsen, D. S., mar. 2022, I: Nordic Journal of Nursing Research. 42, 1, s. 28-41

Diagnosis, treatment, and outcome of primary CNS lymphoma—a single-center experience

Wismann, J., Sommer-Sørensen, R. H., Kofoed, M. S., Halle, B., Pedersen, C. B., Schulz, M. K., Grønhøj, M. H., **Larsen, T. S.,** Møller, M. B. & Poulsen, F. R., maj 2022, I: Acta Neurochirurgica. 164, 5, s. 1365-1373

An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves

Wysocki, O., Zhou, C., Rogado, J., Huddar, P., Shotton, R., Tivey, A., Albiges, L., Angelakas, A., Arnold, D., Aung, T., Banfill, K., Baxter, M., Barlesi, F., Bayle, A., Besse, B., Bhogal, T., Boyce, H., Britton, F., Calles, A., Castelo-Branco, L., Copson, E., Croitoru, A., Dani, S. S., Dickens, E., Eastlake, L., Fitzpatrick, P., Foulon, S., **Frederiksen, H**., Ganatra, S., Gennatas, S., Glenthøj, A., Gomes, F., Graham, D. M., Hague, C., Harrington, K., Harrison, M., Horsley, L., Hoskins, R., Hudson, Z., Jakobsen, L. H., Joharatnam-Hogan, N., Khan, S., Khan, U. T., Khan, K., Lewis, A., Massard, C., Maynard, A., McKenzie, H., Michielin, O., Mosenthal, A. C. & on behalf of the ESMO Co-Care, 16. aug. 2022, I: Cancers . 14, 16, 15 s., 3931.